Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Immutep's current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Website: immutep.com

Employees: 20 - 49

HQ: N/A

Location: Sydney, NSW, AU

Revenue: 1 - 2.5 Million

Immutep Limited is a biotechnology company that focuses on developing immunotherapy treatments for cancer and autoimmune diseases. They are headquartered in Sydney, Australia and have a strong presence in the global biotech industry. If you're looking for contact information for Immutep Limited, ConnectPlex is the right place to be. Our B2B lead generation products provide access to millions of company records, including key contact information for Immutep Limited. At ConnectPlex, we understand the importance of connecting with the right people in any organization. Our AI-based algorithms help you find the most relevant contact information for Immutep Limited, so you can get in touch with decision-makers and industry experts quickly and easily. Whether you're looking to collaborate, invest, or do business with Immutep Limited, ConnectPlex is your go-to resource for all your lead generation needs. Start your search today and discover how ConnectPlex can help you connect with the people who matter most in the biotech industry.

Immutep Limited is a biotechnology company that specializes in the development of immunotherapeutic products for the treatment of cancer and autoimmune diseases. Based in Sydney, Australia, the company is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States. Immutep's current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. In addition, the company is developing an agonist of LAG-3 (IMP761) for autoimmune disease, as well as other LAG-3 products, including antibodies for immune response modulation, in collaboration with large pharmaceutical partners. Immutep's mission is to leverage its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. The company's management team includes experienced executives with a strong track record in the biotechnology industry. Marc Voigt serves as CEO, Deanne Miller as Chief Operating Officer, and Russell Howard as Chairman of the Board. With its cutting-edge technology and experienced leadership, Immutep is poised to make a significant impact in the field of immunotherapy and improve the lives of patients around the world.

Immutep is a biotech company that works on creating new treatments for cancer and autoimmune diseases. They are experts in a protein called LAG-3 and are using it to make different products that can help the immune system fight diseases. Their lead product, eftilagimod alpha, is being tested in cancer and infectious diseases and is a first-of-its-kind treatment that helps activate the immune system. They are also working on a different product that can help with autoimmune diseases. Immutep is a global company and is listed on stock exchanges in Australia and the United States.